Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy

NCT01068470 is registered in ClinicalTrials.gov with Loma Linda University as lead sponsor.

NCT NCT01068470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01068470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
Lead sponsor
Loma Linda University
Phase
Observational
Overall status
Terminated
Start date
November 30, 2009
Completion date
March 31, 2012
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, melanoma